Transparency throughout the production chain-a way to reduce pollution from the manufacturing of pharmaceuticals?

Regulatory Toxicology and Pharmacology

Volumn 53, Issue 3, 2009, Pages 161-163

  Joakim Larsson, D G ^a   Fick, Jerker ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

Bulk drugs; Manufacture; Pollution; Regulations; Waste water treatment

Indexed keywords

ARTICLE; DRUG INDUSTRY; DRUG MANUFACTURE; GOVERNMENT REGULATION; INDIA; INDUSTRIAL WASTE; POLLUTION; PRIORITY JOURNAL; SWEDEN; WASTE WATER MANAGEMENT; FINANCIAL MANAGEMENT; LEGISLATION AND JURISPRUDENCE; ORGANIZATION AND MANAGEMENT; PREVENTION AND CONTROL; STANDARDS;

APIS;

DRUG INDUSTRY; ENVIRONMENTAL POLLUTION; GOVERNMENT REGULATION; INDIA; OUTSOURCED SERVICES; SWEDEN;

EID: 62549104174     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2009.01.008     Document Type: Note

References (14)

1. Bisaraya S.C., and Patil D.M. Determination of salicylic acid and phenol (ppm level) in effluent from aspirin plant. Res. Indus. 38 (1993) 170-172
2. Carlsson, G., Örn, S., Larsson, D.G.J., 2009. Effluent from bulk drug production is toxic to aquatic vertebrates. Environ. Toxicol. Chem. doi:10.1897/08-524.1.
3. Cars O., Högberg L.D., Murray M., Nordberg O., Sivaraman S., Stålsby Lundborg C., So A.D., and Tomson G. Meeting the challenge of antibiotic resistance. Br. Med. J. 337 (2008) a1438
4. China Daily, 2007. Drug factories ordered to clean up (http://www.chinadaily.com.cn/language_tips/cdaudio/2007-09/05/content_6082495.htm. Accessed September 8, 2008.
5. CPA. 2006. Competition in the World APIs Market. Chemical pharmaceutical generic association, Milan, Italy. Report Available at www.cpa-italy.org
6. Cui C.W., Ji S.L., and Ren H.Y. Determination of steroid estrogens in wastewater treatment plant of a contraceptives producing factory. Environ. Monitor. Assess. 121 (2006) 409-419
7. Hoerger, C.C., Dörr, B., Schlienger, C., Straub, J.O., 2009. Environmental risk assessment for the galenical formulation of solid medicinal products at Roche Basle, Switzerland. Integ. Environ. Assess. Management. doi:10.1897/IEAM_2008-049.1.
8. Holm J.V., Rugge K., Bjerg P., and Christensen T.H. Occurrence and distribution of pharmaceutical organic compounds in the groundwater downgradient of a landfill (Grindsted, Denmark). Environ. Sci. Technol. 29 (1995) 1415-1420
9. Larsson D.G.J., De Pedro C., and Paxéus N. Effluent from drug manufactures contains extremely high levels of pharmaceuticals. J. Hazard Mater. 148 (2007) 751-755
10. Larsson D.G.J. Drug production facilities-an overlooked discharge source for pharmaceuticals to the environment. In: Kümmerer K. (Ed). Pharmaceuticals in the Environment. Sources, Fate, Effects and Risks (2008), Springer, Berlin p 37-42 Heidelberg, New York
11. Li D., Yang M., Hu J., Ren L., Zhang Y., and Li K. Determination and fate of oxytetracycline and related compounds in oxytetracycline production wastewater and the receiving river. Environ. Toxicol. Chem. 27 (2008) 80-86
12. Martinez J.L. Antibiotics and antibiotic resistance genes in natural environments. Science 321 (2008) 365-367
13. Stenberg, I. LIF vill införa globala miljökrav. Läkemedelsvärlden. 2007 (in Swedish) http://www.lakemedelsvarlden.se/zino.aspx?articleID=10963. Accessed September 8, 2008.
14. Züehlke S., Duennbier U., and Heberer T.H. Detection and identification of phenazone-type drugs and their microbial metabolites in ground and drinking water applying solid-phase extraction and gas chromatography with mass spectrometric detection. J. Chromatogr. A 1050 (2004) 201-209